NXGL NEXGEL, INC.

CIK 0001468929 50 ready 8-Ks latest August 21, 2026, 4:42 PM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 2 baseline Risk accumulating: repeated leadership change (7)

Ready 8-Ks 50

Latest filing August 21, 2026, 4:42 PM ET

Top materiality 1.00

Event mix other_material ×18 · earnings ×12 · leadership ×11

Sentiment 18 pos · 4 neg · 28 neu

Latest earnings reported 2026-Q2

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for NXGL

Highest-materiality recent filing

NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M

April 21, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01 item 2.01 item 2.03 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×5◈ Material Agreements ×3◈ Debt Financings ×2◈ M&A Transactions

Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
Raised $6.9M via convertible notes (10% interest, 18-month, $0.60 conversion) and warrants (5-year, $0.80 strike) to fund the deal.

Read filing →

August 21, 2026, 4:42 PM ET leadership materiality 0.75 neutral item 5.02 item 9.01 ◈ executive_change ×3

NexGel terminates CEO Adam Levy, appoints Brian Kieser interim CEO, launches strategic review

Adam R. Levy terminated as CEO without cause effective Aug 21, 2026; resigned from board and all officer positions.
August 17, 2026, 8:15 AM ET earnings materiality 0.80 negative item 2.02 item 9.01

NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails

Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.
July 29, 2026, 5:25 PM ET other material materiality 0.60 neutral item 5.02 item 9.01

NexGel enters new CEO employment agreement with Adam Levy; base salary $375K, option grant of 160K shares

CEO Adam Levy receives base salary of $375,000 per year under new employment agreement effective July 23, 2026.
May 15, 2026, 4:31 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Material Agreements

NexGel closes $1.21M private placement of convertible notes and warrants

Issued $1.21M aggregate principal amount of unsecured convertible notes at $0.60/share initial conversion price.
May 12, 2026, 4:30 PM ET leadership materiality 0.75 positive item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing

Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.
April 24, 2026, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

NexGel receives Nasdaq deficiency notice for bid price below $1; 180 days to cure

Closing bid price of common stock (NXGL) below $1.00 for 30 consecutive business days.
April 21, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01 item 2.01 item 2.03 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×5◈ Material Agreements ×3◈ Debt Financings ×2◈ M&A Transactions

NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M

Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
March 10, 2026, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M

Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.
February 11, 2026, 6:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Debt Financings◈ Material Agreements

NexGel closes $1.8M Series A convertible note; up to $14.9M more for Q1 acquisition

Initial Series A convertible note raised $1,797,381 gross proceeds, bearing 10% interest (18% on default), convertible at $1.244/share with floor $0.2488.
December 11, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 2.02 item 9.01

NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake

NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.
August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

NEXGEL Q2 revenue doubles to $2.88M, guided to $13M and positive EBITDA for FY2025

Revenue $2.88M, +100.3% YoY; gross margin 43.6% vs 20.3% YoY.
August 1, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 8.01 item 9.01

NEXGEL raises ~$1M in registered direct offering and private placement; warrants at $4.25

Registered direct offering of 413,044 shares at $2.30/share; gross proceeds ~$950,000.
July 14, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 2.02 item 9.01

NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches

Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.
May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

NexGel Q1 revenue $2.81M (+121% YoY); gross margin expands to 42.4% from 12.6%

Revenue $2.81M, up 121% YoY from $1.27M; guided Q1 slightly above prior outlook.
March 24, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

NexGel Q4 revenue up 181% to $3.04M, guides 2025 revenue of $13M, positive EBITDA

Q4 revenue $3.04M (up 181% YoY); FY 2024 revenue $8.69M (up 112% YoY).
January 22, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

NEXGEL prelim Q4 rev ~$3M, FY2024 ~$8.6M (+100% YoY); guides FY2025 >$13M, cash flow positive

Preliminary Q4 2024 revenue ~$3.0M; full year ~$8.6M, representing >100% YoY growth for third consecutive year.
November 14, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

NEXGEL Q3 revenue record $2.94M (+141% YoY); gross margin expands to 43.6%

Net loss widened to $754K vs $552K Q3 2023, but improved from $979K Q2 2024; adjusted EBITDA loss narrowed to $347K.
November 12, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 8.01 item 9.01

NEXGEL raises ~$2M in registered direct offering of stock and warrants at $2.75/share

Offering of 727,272 common shares and warrants to buy 363,636 shares at $4.25; gross proceeds ~$2M.
October 10, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

NexGel preannounces record Q3 2024 revenue of $2.85M, +133% YoY, +98% QoQ

Expected revenue $2.85M, up 133% YoY and 98% sequentially, beating prior $2.20M guidance by ~30%.
August 14, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

NEXGEL reports record Q2 revenue of $1.44M, net loss widens to $979K

Record Q2 revenue $1.44M, up 23.4% YoY; gross margin improved to 28.5% from 15.0%.
August 13, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

NEXGEL announces $1.11M registered direct offering of 444K shares and 222K warrants; insiders participate

Gross proceeds of ~$1.11M from sale of 444K shares at $2.50/share and warrants exercisable at $4.25.
July 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

NexGel reports preliminary Q2 revenue of $1.4M (+20% YoY); guides Q3 $2.2M, Q4 $2.6M

Preliminary Q2 2024 revenue of $1.4M, up ~20% YoY and ~10% sequentially.
May 20, 2024, 7:59 PM ET M&A materiality 0.65 positive item 1.01 item 2.01 item 3.02 item 8.01 item 9.01 ◈ M&A Transactions

NexGel acquires Silly George beauty brand for $600k cash+stock plus earn-out

Purchase price: $400k cash, $200k in NXGL common stock, and a 4-year net profit earn-out.
May 13, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY

Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).
April 1, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

NEXGEL reports FY2023 revenue $4.1M (+99.7% YoY); net loss narrows to $3.2M

Revenue $4.1M for FY2023, up 99.7% YoY; Q4 revenue $1.1M, up 110% YoY.
December 29, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 1.01 item 3.02 item 5.02 item 9.01

NexGel enters 2024 employment agreement with CEO Adam Levy, appoints Scott Henry to compensation committee

NexGel entered a one-year employment agreement with CEO Adam Levy, effective Jan 1, 2024, with $325,000 base salary and $70,000 equity grant.
December 11, 2023, 6:59 PM ET other materiality 0.60 positive item 7.01 item 9.01

NEXGEL forms partnership with STADA to distribute OTC health products in North America starting mid-2024

Partnership with STADA Arzneimittel AG, a European consumer health leader, for distribution and commercialization.
December 5, 2023, 6:59 PM ET M&A materiality 0.60 positive item 1.01 item 2.01 item 8.01 item 9.01 ◈ M&A Transactions◈ Material Agreements

NexGel acquires Kenkoderm psoriasis skincare line for $546,500 initial cash plus earn-out

Initial cash payment of $546,500; earn-out up to additional $546,500 based on 2024 performance.

Executive changes

Departed

Adam R. Levy

Director

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Filed: August 21, 2026, 4:42 PM ET

Mr. Levy resigned from the Company’s Board of Directors

Appointed (interim)

Brian Kieser

Interim Chief Executive Officer

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Filed: August 21, 2026, 4:42 PM ET

Effective as of the Separation Date, the Board appointed Brian Kieser to serve as Interim Chief Executive Officer of the Company.

Departed

Adam R. Levy

Chief Executive Officer

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Successor: Brian Kieser
Filed: August 21, 2026, 4:42 PM ET

Effective August 21, 2026 (the “ Separation Date ”), NexGel, Inc. (the “ Company ”) terminated Adam R. Levy’s employment as Chief Executive Officer without Cause (as defined in Mr. Levy’s Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company’s Board of Directors (the “ Board ”) and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.

Appointed

Kevin M. Harris

Director

NXGL · NEXGEL, INC.

Effective: 2026-05-06
Filed: May 12, 2026, 4:30 PM ET

On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors

Appointed

Brian J. Kieser

Director

NXGL · NEXGEL, INC.

Effective: 2026-05-06
Filed: May 12, 2026, 4:30 PM ET

On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors

Departed

Adam Drapczuk

Chief Financial Officer

NXGL · NEXGEL, INC.

Effective: 2026-04-27
Successor: Ian Blackman
Filed: April 30, 2026, 7:59 PM ET

Mr. Blackman succeeds Mr. Drapczuk as the Company’s principal financial officer and principal accounting officer.

Appointed

Ian Blackman

Chief Financial Officer

NXGL · NEXGEL, INC.

Effective: 2026-04-27
Filed: April 30, 2026, 7:59 PM ET

the Board of Directors of the Company (the “ Board ”) appointed Ian Blackman, age 58, as Chief Financial Officer of NexGel, Inc. (the “ Company ”), effective April 27, 2026.

Appointed

Joseph F. McGuire

Chief Financial Officer

NXGL · NEXGEL, INC.

Filed: January 6, 2025, 6:59 PM ET

Joseph F. McGuire Appointment as Chief Financial Officer

Departed

Miranda J. Toledano

Director; Chairperson of Audit Committee; member of Nominating and Corporate Governance Committee

NXGL · NEXGEL, INC.

Effective: 2024-03-31
Filed: January 16, 2024, 6:59 PM ET

On January 9, 2024, Miranda J. Toledano notified NexGel, Inc. (the “ Company ”) of her intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of March 31, 2024.

Departed

David Stefansky

Director

NXGL · NEXGEL, INC.

Effective: 2023-12-31
Filed: December 12, 2023, 6:59 PM ET

On December 7, 2023, David Stefansky notified NexGel, Inc. (the “ Company ”) of his intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of December 31, 2023 to pursue other business ventures.

Departed

Yaakov Spinrad

Director

NXGL · NEXGEL, INC.

Effective: 2023-01-16
Filed: January 17, 2023, 6:59 PM ET

On January 16, 2023, Yaakov Spinrad resigned as a member of the Board.

Appointed

Scott R. Henry

Director

NXGL · NEXGEL, INC.

Effective: 2023-01-16
Filed: January 17, 2023, 6:59 PM ET

On January 16, 2023, Scott R. Henry (the “ Board Appointees ”) was appointed to the board of directors (the “ Board ”) of NexGel, Inc.

Earnings & guidance

2026-Q2 EPS reported -$0.54 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.60 · Most common event other_material

18 positive 4 negative 28 neutral

source · NXGL on sec.gov